Cell membrane material for amplifying T regulatory cells, feeding matrix, system, kit, method for amplifying T regulatory cells and application
By expressing IL-21 and CD40L proteins on cell membrane materials, a three-dimensional environment was created, and the problem of low in vitro expansion efficiency of Treg cells was solved, and efficient Treg cell expansion was achieved, which was suitable for clinical applications.
Patent Information
- Application Number
- CN202310578561.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-22
- Publication Date
- 2024-11-22
AI Technical Summary
In the prior art, the in vitro amplification efficiency of Treg cells is low, which leads to inconvenience and difficulties in clinical applications, and requires a fast and efficient amplification method.
It provides a cell membrane material that expresses IL-21 and CD40L proteins on the surface, and is derived from malignant tumor cells with multidirectional differentiation potential. It is used to create a three-dimensional environment for cell expansion in the body and promote the rapid expansion of Treg cells.
Through this method, the amplification efficiency of Treg cells can exceed 10,000 times within 7 days, which is easy to operate, low cost, and the material is sterile and non-toxic, and is suitable for direct use in clinical applications.
Smart Images

Figure CN118995627A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and relates to a cell membrane material, a feeder matrix, a system, a kit, a method and application of amplifying T regulatory cells, and also relates to a method for preparing the cell membrane material. Background Art
[0002] Regulatory T cells (Treg cells) are a type of cell subset related to the body's immune balance. They can actively inhibit the function of ordinary T cells, maintain the immune system's tolerance to its own components, and keep the body in immune homeostasis. Treg cells are mainly distributed in the human thymus, peripheral blood, lymphoid organs, and umbilical vein blood. They are characterized by the expression of Foxp3, CD25, and CD4. Research in the past 20 years has confirmed that autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and type 1 diabetes (T1D) are caused by an imbalance between the body's Treg cells and effector T cells (Teff). Clinical trial data show that organ-specific immune diseases, especially those caused by a lack of nTreg cells (natural regulatory T cells), can be treated by reconstructing Foxp3+nTreg cells. Clinical experiments have shown that the infusion of small doses of IL-2 can cause Treg cells to proliferate without causing the expansion of effector T cells. In clinical practice, in order to prevent GvHD, Treg cells stimulated by the donor's peripheral blood monocytes are usually expanded in vitro, and then these Treg cells and hematopoietic stem cells are infused into the patient together.
[0003] According to their sources, Treg can be divided into naturally occurring natural regulatory T cells (nTreg) and induced adaptive regulatory T cells (aTreg or iTreg). Natural regulatory T cells are mainly CD4+CD127low / -CD25+ Treg cells, accounting for about 5% to 10% of CD4+T cells in peripheral blood and spleen. In addition to expressing CD4 and CD25 molecules, their characteristic marker is their high expression of transcription factor Foxp3; adaptive regulatory T cells include Tr1, Th3 and other cells, which are developed from peripheral naive T cells under the induction of small doses of antigens or immunosuppressive cytokines, and mainly secrete IL-10 and TGF-β to play a negative immune regulatory role.
[0004] Tregs account for 1% to 2% of the human body's peripheral blood lymphocytes. Due to the small number of Treg cells and the low efficiency of in vitro expansion of Treg cells, this has brought great inconvenience and difficulty to the use of Treg cell therapy in clinical practice. Therefore, developing a method that can quickly and efficiently expand Treg cells is very important for promoting the clinical use of this therapy. Summary of the invention
[0005] In view of the above-mentioned shortcomings of the prior art, an object of the present invention is to provide a cell membrane material and a feeder matrix for expanding T regulatory cells, so as to solve the problems in the prior art.
[0006] To achieve the above-mentioned purpose and other related purposes, the present invention provides a cell membrane material for amplifying T regulatory cells, wherein the surface of the cell membrane expresses IL-21 and CD40L proteins, and the cell membrane is derived from malignant tumor cells of the hematopoietic system with multidirectional differentiation potential, and the malignant tumor cells can spontaneously differentiate into identifiable progenitor cells of the erythroid, granulocyte or monocytic lineages. IL-21 and CD40L proteins are expressed on the surface of the cell membrane material, creating a three-dimensional environment for cell amplification in vivo, which is conducive to the rapid amplification of Treg cells.
[0007] T regulatory cells (Tregs) are a type of T cell subset that controls autoimmune reactivity in the body. Regulatory T cells can be divided into naturally occurring natural regulatory T cells (n T-regs) and induced adaptive regulatory T cells (a T-regs or i T-regs), such as Th3 and Tr1. In addition, there are CD8 Tregs, NKT cells, etc., which are closely related to the occurrence of autoimmune diseases, and their abnormal expression can lead to autoimmune diseases. Among them, Tr1 cells secrete IL-10; Th3 cells secrete TGF-β.
[0008] Interleukin-21 (IL-21) is secreted by activated CD4+T cells. Its molecular structure is similar to IL-15. It participates in regulating B cell proliferation and cooperates with IL-15 to promote the proliferation of bone marrow precursor cells and the proliferation, differentiation and cytotoxic activity of NK cells.
[0009] CD40L, also known as gp39, tumor necrosis factor-associated activation protein (TNF associated activation protein, TRAP), and T cell-B cell-activating molecule (T-BAM), is a 33kD type II transmembrane glycoprotein with a total of 266aa, including 214 amino acids in the extracellular domain, and has a high homology with TNF at the amino acid level.
[0010] As certain embodiments of the present invention, the IL-21 is connected to a transmembrane protein, and the amino acid sequence of the fusion protein containing IL-21, a connector and a transmembrane protein is shown in SEQ ID NO.2.
[0011] As certain embodiments of the present invention, the amino acid sequence of CD40L is shown as SEQ ID NO.4.
[0012] As certain embodiments of the present invention, the cell membrane is derived from human K562 cells.
[0013] K562 cells are artificially cultured cells of myeloid leukemia. The type of erythroleukemia K562 cells is lymphoblastoid cells derived from a female patient in the blast phase of chronic myeloid leukemia.
[0014] As certain embodiments of the present invention, the cell positive rate of IL-21 and CD40L proteins expressed on the cell membrane is 90%.
[0015] The present invention also provides a feeder matrix for amplifying T regulatory cells, wherein the feeder matrix comprises IL-21 and CD40L proteins, and / or the cell membrane material.
[0016] As certain embodiments of the present invention, the amino acid sequence of IL-21 is shown as SEQ ID NO.5, and the amino acid sequence of the CD40L protein is shown as SEQ ID NO.4.
[0017] As certain embodiments of the present invention, the molar ratio of IL-21 and CD40L protein is 1:1.
[0018] Preferably, the cell positive rate of IL-21 and CD40L proteins expressed on the cell membrane is 90%.
[0019] The present invention also provides a system for expanding T regulatory cells, the system comprising the feeder matrix. Optionally, the system further comprises T regulatory cells co-cultured with the feeder matrix.
[0020] As certain embodiments of the present invention, the amino acid sequence of IL-21 is shown as SEQ ID NO.5, and the amino acid sequence of the CD40L protein is shown as SEQ ID NO.4.
[0021] As certain embodiments of the present invention, the molar ratio of IL-21 and CD40L protein is 1:1.
[0022] The present invention also provides a kit for amplifying T regulatory cells, the kit comprising the feeder matrix. Optionally, the kit also comprises T regulatory cells co-cultured with the feeder matrix.
[0023] As certain embodiments of the present invention, the amino acid sequence of IL-21 is shown as SEQ ID NO.5, and the amino acid sequence of the CD40L protein is shown as SEQ ID NO.4.
[0024] As certain embodiments of the present invention, the molar ratio of IL-21 and CD40L protein is 1:1.
[0025] The present invention also provides a method for amplifying T regulatory cells, the method comprising co-culturing T regulatory cells with IL-21 and CD40L proteins and / or the cell membrane material, or the feeder matrix. The method can achieve rapid in vitro amplification of Treg cells, and the amplified cells can continue to grow normally and healthily.
[0026] As certain embodiments of the present invention, the amino acid sequence of IL-21 is shown as SEQ ID NO.5, and the amino acid sequence of the CD40L protein is shown as SEQ ID NO.4.
[0027] As certain embodiments of the present invention, the IL-21 and CD40L proteins, the cell membrane material and the feeder matrix are coated on the surface of an amplification device or an amplification apparatus.
[0028] As certain embodiments of the present invention, the seeding density of the T regulatory cells is 10 4 -5*10 6 Pieces / ml.
[0029] As certain embodiments of the present invention, the T regulatory cells are peripheral blood cells.
[0030] The present invention also provides the use of IL-21 and CD40L proteins and / or the cell membrane material, or the feeder matrix, or the system, or the kit in amplifying T regulatory cells.
[0031] The present invention also provides a method for preparing the feeder matrix, comprising the following steps: (1) cloning a plasmid that recombinantly expresses IL-21 and CD40L proteins; (2) transfecting cells with the plasmid expressing IL-21 and CD40L proteins in step (1); the cells are malignant tumor cells of the hematopoietic system with multidirectional differentiation potential, and the malignant tumor cells can spontaneously differentiate into identifiable progenitor cells of the erythroid, granulocyte or monocytic lineages; (3) collecting and disrupting the cells transfected in step (2), separating and obtaining cell membrane fragments; optionally, (4) mixing the cell membrane fragments obtained in step (3), IL-21 and CD40L proteins.
[0032] As certain embodiments of the present invention, the transfection in step (2) is achieved by electroporation.
[0033] As certain embodiments of the present invention, the plasmids for recombinantly expressing IL-21 and CD40L proteins in step (1) are the same plasmid or different plasmids.
[0034] As certain embodiments of the present invention, the molar ratio of IL-21 and CD40L protein is 1:1.
[0035] As described above, the cell membrane material, feeder matrix, system, kit, method and application for expanding T regulatory cells of the present invention have the following beneficial effects:
[0036] The cell membrane material prepared by the present invention, which can efficiently express transmembrane cytokines on the cell membrane surface, can be used to stimulate the efficient expansion of Treg cells. The test results show that the expansion efficiency of the feeder matrix composed of K562 cell membranes expressing IL-21 and CD40L proteins can be greater than 10 within 7 days. 9 , the amplification efficiency is more than 10,000 times.
[0037] The method of the present invention is simple to operate, low in cost, and is conducive to the rapid expansion of Treg cells. The materials used in the method are all sterile and non-toxic, and can be directly used for Treg cells, or even the cultured Treg cells can be implanted into the body.
[0038] The cell membrane prepared by the present invention is degradable, which provides convenience for subsequent treatment and reduces the probability of contamination. The present invention provides a new approach and method for obtaining a large number of Treg cells in a short time. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 The flow cytometry of the present invention is used to detect the expression of CD40L and IL-21 on the surface of K562 cells. The detection results show that the positive rate of K562 cells expressing CD40L and IL-21 is 90%;
[0040] Figure 2 The results show a comparison of the cell expansion efficiency of Treg cells expanded by the K562 cell membrane method of the present invention and the cell expansion efficiency of Treg cells expanded using only CD40L and IL-21; after using a feeder matrix composed of K562 cell membranes expressing CD40L and IL-21 proteins, the expansion efficiency of Treg cells is increased by more than 10,000 times compared with Treg cells fed with CD40L and IL-21 proteins. DETAILED DESCRIPTION
[0041] The present invention is further described below in conjunction with specific examples, and it should be understood that these examples are only used to illustrate the present invention and are not used to limit the scope of protection of the present invention. Those skilled in the art can easily understand other advantages and effects of the present invention from the content disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.
[0042] It should be understood that the terms used in the examples of the present invention are intended to describe specific embodiments rather than to limit the scope of protection of the present invention; in the present specification and claims, unless otherwise expressly stated, the singular forms "a", "an" and "the" include plural forms. When the examples give numerical ranges, it should be understood that unless otherwise specified in the present invention, both endpoints of each numerical range and any value between the two endpoints can be selected.
[0043] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meanings as those commonly understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, any methods, equipment, and materials of the prior art that are similar or equivalent to the methods, equipment, and materials in the embodiments of the present invention may be used to implement the present invention, based on the prior art mastery of those skilled in the art and the description of the present invention.
[0044] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in the field of molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related fields. These techniques are well described in the literature, see Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, Second edition, Cold Spring Harbor Laboratory Press, 1989 and Third edition, 2001; Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987 and periodic updates; these series METHODS IN ENZYMOLOGY, Academic Press, San Diego; Wolffe, CHROMATINSTRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; METHODS IN ENZYMOLOGY, Vol. 304, Chromatin (PM Wassarman and AP Wolffe, eds.), Academic Press, San Diego, 1999; and METHODS IN MOLECULAR BIOLOGY, Vol. 304, Chromatin (PM Wassarman and AP Wolffe, eds.), Academic Press, San Diego, 1999. BIOLOGY, Vol. 119, Chromatin Protocols (PB Becker, ed.) Humana Press, Totowa, 1999, etc.
[0045] The cell membrane material of the transmembrane cytokine that can be efficiently expressed on the cell membrane surface prepared by the present invention can be used to stimulate the efficient expansion of Treg cells.
[0046] Example 1 Synthesis and Construction of IL-21 and CD40L Expression Plasmids
[0047] CD40 belongs to the tumor necrosis factor (TNF) receptor superfamily member, and is widely expressed on the surface of activated CD4+T cells, CD8+T cells, B cells, dendritic cells (DC), macrophages and other immune cells, as well as non-immune cells such as endothelial cells and platelets. Its ligand CD40L and CD40 are a pair of complementary protein molecules, and belong to the TNF superfamily member. CD40L is similar to CD40, and is also widely expressed in many immune cells, providing the costimulatory signals necessary for T and B cell activation. After CD40L binds to the CD40 molecule, it can crosslink and ligand the membrane CD40 molecule, and then polymerize the CD40 molecule, forming the structural basis and initiating factor of CD40 signal transduction. Therefore, in the present invention, the CD40L molecule is selected as the element for amplifying Treg cells.
[0048] Interleukin 21 (IL-21) can stimulate T cell proliferation and induce activation and expansion of various types of immune cells. The activated immune cells are not prone to apoptosis, and the effect is better than IL-2. In recent years, it has been used as a component of CAR-T amplification in cell therapy and has a good effect on T cell proliferation. Therefore, in the present invention, IL-21 molecules are selected as elements for amplifying Treg cells.
[0049] The nucleic acid and amino acid sequences of IL-21 and CD40L were obtained from the NCBI database, and the IL-21 and CD40L molecules were synthesized respectively by the whole gene synthesis method. Then, the obtained IL-21 sequence and CD40L molecule were constructed into the PCDNA3.1 molecule by the double enzyme digestion method, and the transfection-positive bacteria were expanded and cultured, and the PCDNA3.1-IL-21 and CD40L plasmids were extracted using an endotoxin-free plasmid extraction kit.
[0050] Nucleic acid sequence: (IL-21+linker+transmembrane protein) as shown in SEQ ID NO.1:
[0051] GAATTCATGAGATCCAGTCCTGGCAACATGGAGAGGATTGTCATCTGTCTGATGGTCATCTTCTTGGGGACACTGGTCCACAAATCAAGCTCCCAAGGTCAAGATCGCCACATGATTAGAATGCGTCAACTTATAGATATTGTTGATCAGCTGAAAAATTATGTGAATGACTTGGTCCCTGAATTTCTGCCAGCTCCAGAAGATGTAGAGACAAACTGTGAGTGGTCAGCTTTTTCCTGTTTTCAGAAGGCCCAACTAAAGTCAGCAAATACAGGAAACAATGAAAGGATAATCAATGTATCAATTAAAAAGCTGAAGAGGAAACCACCTTCCACAAATGCAGGGAGAAGACAGAAACACAGACTAACATGCCCTTCATGTGATTCTTATGAGAAAAAACCACCCAAAGAATTCCTAGAAAGATTCAAATCACTTCTCCAAAAGATGATTCATCAGCATCTGTCCTCTAGAACACACGGAAGTGAAGATTCCTGAGCGGCCGC
[0052] The amino acid sequence is shown in SEQ ID NO.2:
[0053] MRSSPGNMERIVICLMVIFLGTLVHKSSSQGQDRHMIRMRQLIDIVDQLKNYVNDLVPEFLPAPEDVETNCEWSAFSCFQKAQLKSANTGNNERIINVSIKKLKRKPPSTNAGRRQKHRLTCPSCDSYEKKPPKEFLERFKSLLQKMIHQHLSSRTHGSEDS
[0054] The CD40L nucleic acid sequence is shown in SEQ ID NO.3:
[0055] GAATTCGCCGCCACCATCGAAACATACAACCAAACTTCTCCCCGATCTGCGGCCACTGGACTGCCCATCAGCATGAAAATTTTTATGTATTTACTTACTGTTTTTCTTATCACCCAGATGATTGGGTCAGCACTTTTTGCTGTGTATCTTCATAGAAGGTTGGACAAGATAGAAGATGAAAGGAATCTTCATGAAGATTTTGTATTCATGAAAACGATACAGAGATGCAACACAGGAGAAAGATCCTTATCCTTACTGAACTGTGAGGAGATTAAAAGCCAGTTTGAAGGCTTTGTGAAGGATATAATGTTAAACAAAGAGGAGACGAAGAAAGAAAACAGCTTTGAAATGCAAAAAGGTGATCAGAATCCTCAAATTGCGGCACATGTCATAAGTGAGGCCAGCAGTAAAACAACATCTGTGTTACAGTGGGCTGAAAAAGGATACTACACCATGAGCAACAACTTGGTAACCCTGGAAAATGGGAAACAGCTGACCGTTAAAAGACAAGGACTCTATTATATCTATGCCCAAGTCACCTTCTGTTCCAATCGGGAAGCTTCGAGTCAAGCTCCATTTATAGCCAGCCTCTGCCTAAAGTCCCCCGGTAGATTCGAGAGAATCTTACTCAGAGCTGCAAATACCCACAGTTCCGCCAAACCTTGCGGGCAACAATCCATTCACTTGGGAGGAGTATTTGAATTGCAACCAGGTGCTTCGGTGTTTGTCAATGTGACTGATCCAAGCCAAGTGAGCCATGGCACTGGCTTCACGTCCTTTGGCTTACTCAAACTCTAGGCGGCCGC
[0056] The amino acid sequence of CD40L is shown in SEQ ID NO.4:
[0057] MIETYNQTSPRSAATGLPISMKIFMYLLTVFLITQMIGSALFAVYLHRRLDKIEDERNLHEDFVFMKTIQRCNTGERSLSLLNCEEIKSQFEGFVKDIMLNKEETKKENSFEMQKGDQNPQIAAHVISEA SSKTTSVLQWAEKGYYTMSNNLVTLENGKQLTVKRQGLYYIYAQVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTHSSAKPCGQQSIHLGGVFELQPGASVFVNVTDPSQVSHGTGFTSFGLLKL
[0058] The amino acid sequence of IL-21 is shown in SEQ ID NO.5:
[0059] MRSSPGNMERIVICLMVIFLGTLVHKSSSQGQDRHMIRMRQLIDIVDQLKNYVNDLVPEFLPAPEDVETNCEWSAFSCFQKAQLKSANTGNNERIINVSIKKLKRKPPSTNAGRRQKHRLTCPSCDSYEKKPPKEFLERFKSLLQKMIHQHLSSRTHGSEDS
[0060] Example 2 Preparation of cell membrane materials expressing IL-21 and CD40L proteins
[0061] 2.1 Transfection of K562 Cells
[0062] Malignant tumor cells of the hematopoietic system with multidirectional differentiation potential can spontaneously differentiate into identifiable progenitor cells of the erythroid, granulocyte and monocytic lineages. In this embodiment, K562 cells were selected.
[0063] 2.1.1 Recovery and culture of K562 cells
[0064] Culture conditions: 1640 medium 10% FBS, subculture method: maintain cell density at 10 5 -10 6 / ml, and change the medium 2-3 times a week.
[0065] Electrotransfection:
[0066] Use BIO-RAD's electroporator to electroporate the plasmids of PCDNA3.1-IL-21 and PCDNA3.1-CD40L in steps as follows:
[0067] 0.2cm electroporation cup, cell density of 10x10^6 cells / ml, DNA dosage of 2μg, electroporation solution volume of 100μl, voltage of 130V, capacitance of 950μF. After electroporation, 1640 medium was added quickly, and cells were transferred to culture bottles for recovery. Flow cytometry was used to analyze the expression of CD40L and IL-21 on the cell membrane. Figure 1 The results showed that after two electroporations, the positive expression rates of CD40L and IL-21 in K562 cells exceeded 90%.
[0068] Example 3 Preparation of cell membrane for Treg cell expansion
[0069] The K562 cell density was increased to 10 9 -10 10 / ml, collect the cells, wash the cells with PBS, add 10mM tris hydrochloric acid solution, stir at 4℃ for 2 hours to break the cells, and then centrifuge at low temperature for 30 minutes, collect the precipitate, wash it 3 times with 10mM tris hydrochloric acid solution, centrifuge at low temperature and high speed for 10 minutes, resuspend the precipitate with PBS to obtain K562 cell membrane material.
[0070] Example 4 Efficiency of K562 cell membrane expansion of Treg cells
[0071] First, peripheral blood mononuclear cells (PBMCs) were isolated by gradient centrifugation, and CD4+CD127low / -CD25+ Treg cells were isolated by CliniMACS. T25 cell culture flasks were coated with K562 cell membranes containing equal concentrations of IL-21 and CD40L proteins, and free IL-21 and CD40L cytokines (the ratio of these two cytokines was 1:1), respectively. 5 Treg cells of 100 cells / ml were added to the above T25 culture flasks for culture. After 7 days of culture, the Treg cells were counted and the expansion efficiency was calculated.
[0072] The experimental results showed that the proliferation efficiency of K562 cell membrane expressing IL-21 and CD40L protein can be greater than 10 within 7 days. 9 The expansion efficiency of Treg cells is more than 10,000 times. However, the expansion multiple of Treg cells treated with equal concentrations of IL-21 and CD40L protein is only 1,000 times. For specific expansion efficiency, see Figure 2 .
[0073] The above is only a preferred embodiment of the present invention, and is not any formal or substantial limitation of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and supplements without departing from the method of the present invention, and these improvements and supplements should also be regarded as the protection scope of the present invention. Any technician familiar with this profession, without departing from the spirit and scope of the present invention, can make some changes, modifications and evolutions of the technical content disclosed above, which are equivalent embodiments of the present invention; at the same time, any changes, modifications and evolutions of any equivalent changes made to the above embodiments based on the essential technology of the present invention are still within the scope of the technical solution of the present invention.
Claims
1. A cell membrane material for amplifying T regulatory cells, characterized in that: The cell membrane expresses IL-21 and CD40L proteins on its surface, and the cell membrane is derived from a malignant tumor cell of the hematopoietic system with multidirectional differentiation potential, and the malignant tumor cell can spontaneously differentiate into identifiable progenitor cells of the erythroid, granulocyte or monocytic lineages; Preferably, the IL-21 is linked to a transmembrane protein, and the amino acid sequence of the fusion protein containing IL-21, a linker and a transmembrane protein is as shown in SEQ ID NO.2; Preferably, the amino acid sequence of CD40L is as shown in SEQ ID NO.4; Preferably, the cell membrane is derived from human K562 cells; Preferably, the cell positive rate of IL-21 and CD40L proteins expressed on the cell membrane is 90%.
2. A feeder matrix for expanding T regulatory cells, characterized in that The feeding matrix comprises IL-21 and CD40L proteins and / or the cell membrane material according to claim 1; Preferably, the amino acid sequence of IL-21 is as shown in SEQ ID NO.5, and the amino acid sequence of CD40L protein is as shown in SEQ ID NO.4; Preferably, the cell positive rate of IL-21 and CD40L proteins expressed on the cell membrane is 90%; Preferably, the molar ratio of IL-21 to CD40L protein is 1:
1.
3. A system for expanding T regulatory cells, characterized in that The system comprises the feeder matrix of claim 2; optionally, the system further comprises T regulatory cells co-cultured with the feeder matrix; Preferably, the amino acid sequence of IL-21 is as shown in SEQ ID NO.5, and the amino acid sequence of CD40L protein is as shown in SEQ ID NO.4; Preferably, the molar ratio of IL-21 to CD40L protein is 1:
1.
4. A kit for amplifying T regulatory cells, characterized in that: The kit comprises the feeder matrix of claim 2; optionally, the kit further comprises T regulatory cells co-cultured with the feeder matrix; Preferably, the amino acid sequence of IL-21 is as shown in SEQ ID NO.5, and the amino acid sequence of CD40L protein is as shown in SEQ ID NO.4; Preferably, the molar ratio of IL-21 to CD40L protein is 1:
1.
5. A method for expanding T regulatory cells, characterized in that: The method comprises co-culturing T regulatory cells with IL-21 and CD40L proteins and / or the cell membrane material of claim 1 or the feeder matrix of claim 2; Preferably, the amino acid sequence of IL-21 is as shown in SEQ ID NO.5, and the amino acid sequence of CD40L protein is as shown in SEQ ID NO.
4.
6. The method according to claim 5, characterized in that The IL-21 and CD40L proteins, the cell membrane material and the feeder matrix are coated on the surface of the amplification device or amplification equipment; Or, the seeding density of the T regulatory cells is 10 4 -5*10 6 Pieces / ml.
7. The method according to any one of claims 5 to 6, characterized in that: The T regulatory cells are peripheral blood cells.
8. Use of IL-21 and CD40L proteins, and / or the cell membrane material according to claim 1, or the feeder matrix according to claim 2, or the system according to claim 3, or the kit according to claim 4 in amplifying T regulatory cells.
9. A method for preparing the feeding matrix according to claim 2, characterized in that: The method comprises the following steps: (1) Cloning plasmids that recombinantly express IL-21 and CD40L proteins; (2) transfecting cells with the plasmid expressing IL-21 and CD40L protein of step (1); the cells are malignant tumor cells of the hematopoietic system with multidirectional differentiation potential, and the malignant tumor cells can spontaneously differentiate into identifiable progenitor cells of the erythroid, granulocyte or monocytic lineages; (3) collecting and disrupting the cells transfected in step (2), separating and obtaining cell membrane fragments; Optionally, (4) the cell membrane fragments, IL-21 and CD40L protein obtained in step (3) are mixed.
10. The method according to claim 10, characterized in that The plasmids for recombinantly expressing IL-21 and CD40L proteins in step (1) are the same plasmid or different plasmids; Or the molar ratio of IL-21 and CD40L protein is 1:1.
